{
    "id": 3296,
    "fullName": "EGFR E746_E749del",
    "impact": "deletion",
    "proteinEffect": "gain of function - predicted",
    "geneVariantDescriptions": [
        {
            "description": "EGFR E746_E749del results in the deletion of four amino acids in the protein kinase domain of the Egfr protein from amino acids 746 to 749 (UniProt.org). E746_E749del has not been biochemically characterized, but is predicted to result in a gain of function based on the effect of other EGFR exon 19 deletion mutations (PMID: 16373402, PMID: 16912195, PMID: 23387505).",
            "references": [
                {
                    "id": 21,
                    "pubMedId": 16912195,
                    "title": "Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/16912195"
                },
                {
                    "id": 1804,
                    "pubMedId": 16373402,
                    "title": "Dimerization and the signal transduction pathway of a small in-frame deletion in the epidermal growth factor receptor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/16373402"
                },
                {
                    "id": 441,
                    "pubMedId": 23387505,
                    "title": "Sensitivity and kinase activity of epidermal growth factor receptor (EGFR) exon 19 and others to EGFR-tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23387505"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 1956,
        "geneSymbol": "EGFR",
        "terms": [
            "EGFR",
            "ERBB",
            "ERBB1",
            "HER1",
            "mENA",
            "NISBD2",
            "PIG61"
        ]
    },
    "variant": "E746_E749del",
    "createDate": "02/22/2015",
    "updateDate": "09/10/2018",
    "referenceTranscriptCoordinates": {
        "id": 135608,
        "transcript": "NM_005228",
        "gDna": "chr7:g.55174774_55174785del12",
        "cDna": "c.2237_2248del12",
        "protein": "p.E746_E749delELRE",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 9658,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of NPS-1034 and Iressa (gefitinib) inhibited EGFR, MET, and AXL activity and decreased viability of an Iressa (gefitinib)-resistant non-small cell lung cancer cell line that harbors EGFR E746_A750del and EGFR T790M, as well as MET amplification and over expression of AXL, in culture (PMID: 24165158).",
            "molecularProfile": {
                "id": 26948,
                "profileName": "AXL over exp EGFR E746_E749del EGFR T790M MET amp"
            },
            "therapy": {
                "id": 5116,
                "therapyName": "Gefitinib + NPS-1034",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7367,
                    "pubMedId": 24165158,
                    "title": "MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24165158"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9659,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of NPS-1034 and Tarceva (erlotinib inhibited EGFR, MET, and AXL activity and decreased viability of a Tarceva (erlotinib)-resistant non-small cell lung cancer cell line that harbors EGFR E746_A750del and EGFR T790M, as well as MET amplification and over expression of AXL, in culture (PMID: 24165158).",
            "molecularProfile": {
                "id": 26948,
                "profileName": "AXL over exp EGFR E746_E749del EGFR T790M MET amp"
            },
            "therapy": {
                "id": 5117,
                "therapyName": "Erlotinib + NPS-1034",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7367,
                    "pubMedId": 24165158,
                    "title": "MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24165158"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 3112,
            "profileName": "EGFR E746_E749del",
            "profileTreatmentApproaches": [
                {
                    "id": 4650,
                    "name": "EGFR Inhibitor 2nd gen",
                    "profileName": "EGFR E746_E749del"
                },
                {
                    "id": 4652,
                    "name": "HER inhibitor (Pan)",
                    "profileName": "EGFR E746_E749del"
                },
                {
                    "id": 4649,
                    "name": "EGFR Inhibitor 1st gen",
                    "profileName": "EGFR E746_E749del"
                },
                {
                    "id": 4648,
                    "name": "EGFR Inhibitor (Pan)",
                    "profileName": "EGFR E746_E749del"
                },
                {
                    "id": 4651,
                    "name": "EGFR Inhibitor 3rd gen",
                    "profileName": "EGFR E746_E749del"
                }
            ]
        },
        {
            "id": 26948,
            "profileName": "AXL over exp EGFR E746_E749del EGFR T790M MET amp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 135608,
            "transcript": "NM_005228",
            "gDna": "chr7:g.55174774_55174785del12",
            "cDna": "c.2237_2248del12",
            "protein": "p.E746_E749delELRE",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}